Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, Jiangsu, China.
J Cell Mol Med. 2013 Oct;17(10):1207-17. doi: 10.1111/jcmm.12131. Epub 2013 Sep 23.
The successful long-term use of taxane for cancer therapy is often prevented by the development of drug resistance in clinic. Thus, exploring the mechanisms involved is a first step towards rational strategies to overcome taxane resistance. Taxane resistance-related microRNA (miRNAs) are under investigation and miRNAs could induce the taxane resistance of tumour cells by regulating cell cycle distribution, survival and/or apoptosis pathways, drug transports, epithelial-mesenchymal transition and cancer stem cell. This article summarizes current research involving miRNAs as regulators of key target genes for tanxanxe chemoresistance and discusses the complex regulatory networks of miRNAs. Also, the authors will envisage future developments towards the potential use of targeting miRNAs as a novel strategy for improving response of tumour patients to taxane. miRNAs play critical roles in taxane chemoresistance and the miRNA-based therapies will be helpful for overcoming drug resistance and developing more effective personalized anti-cancer treatment strategies. Further research studies should be performed to promote therapeutic-clinical use of taxane resistance-related miRNAs in cancer patients, especially in those patients with taxane-resistant cancers.
紫杉烷类药物在癌症治疗中的长期应用取得成功，但临床上常因产生耐药性而受阻。因此，探索相关机制是制定合理策略克服紫杉烷类耐药性的第一步。紫杉烷耐药相关 microRNA（miRNA）正在研究中，miRNA 可以通过调节细胞周期分布、存活和/或细胞凋亡途径、药物转运、上皮-间充质转化和癌症干细胞，诱导肿瘤细胞对紫杉烷类药物产生耐药性。本文总结了 miRNA 作为调节紫杉烷类化疗耐药关键靶基因的调节剂的最新研究，并讨论了 miRNA 的复杂调控网络。作者还将展望针对 miRNA 的靶向治疗作为提高肿瘤患者对紫杉烷类药物反应的新策略的潜在应用的未来发展。miRNA 在紫杉烷类耐药中发挥关键作用，基于 miRNA 的治疗方法将有助于克服耐药性并制定更有效的个体化抗癌治疗策略。应进一步开展研究，以促进紫杉烷耐药相关 miRNA 在癌症患者中的治疗-临床应用，特别是在紫杉烷耐药性癌症患者中。
